Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first- line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).

被引：5
|
作者：
Tahara, Makoto
Kiyota, Naomi
Yokota, Tomoya
Hasegawa, Yasuhisa
Muro, Kei
Takahashi, Shunji
Onoe, Takuma
Homma, Akihiro
Taguchi, Jun
Suzuki, Masami
Minato, Koichi
Yane, Katsunari
Ueda, Shinya
Hara, Hiroki
Saijo, Ken
Yamanaka, Takeharu
机构：
[1] Natl Canc Ctr Hosp East, Chiba, Japan
[2] Kobe Univ Hosp, Div Med Oncol & Hematol, Dept Med, Kobe, Hyogo, Japan
[3] Grad Sch Med, Kobe, Hyogo, Japan
[4] Shizuoka Canc Ctr, Shizuoka, Japan
[5] Aichi Caner Ctr, Nagoya, Aichi, Japan
[6] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[7] Ctr Canc Chemotherapy, Tokyo, Japan
[8] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[9] Hyogo Canc Ctr, Dept Med Oncol, Akashi, Hyogo, Japan
[10] Hokkaido Univ, Grad Sch Med, Dept Otolaryngol Head & Neck Surg, Sapporo, Hokkaido, Japan
[11] Hokkaido Univ Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan
[12] Gunma Prefectural Canc Ctr, Ota, Japan
[13] Gunma Prefectural Canc Ctr, Div Resp Med, Ota Shi, Japan
[14] Nara Hosp Kinki Univ, Fac Med, Ikoma, Japan
[15] Kinki Univ, Dept Med Oncol, Fac Med, Osaka, Japan
[16] Saitama Canc Ctr Hosp, Dept Gastroenterol, Saitama, Japan
[17] Tohoku Univ, Sendai, Miyagi, Japan
[18] Yokohama City Univ, Dept Biostat, Yokohama, Kanagawa, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.6026
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6026
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Approval Summary: Cetuximab in Combination With Cisplatin or Carboplatin and 5-Fluorouracil for the First-Line Treatment of Patients With Recurrent Locoregional or Metastatic Squamous Cell Head and Neck Cancer
    Cohen, Martin H.
    Chen, Huanyu
    Shord, Stacy
    Fuchs, Chana
    He, Kun
    Zhao, Hong
    Sickafuse, Sharon
    Keegan, Patricia
    Pazdur, Richard
    ONCOLOGIST, 2013, 18 (04): : 460 - 466
  • [42] Clinical phase II evaluation of paclitaxel in combination with cisplatin in metastatic or recurrent squamous cell carcinoma of the head and neck
    Thodtmann, R
    Theiss, F
    Kemmerich, M
    Heinrich, B
    Laubenbacher, C
    Quasthoff, S
    Kau, R
    Herzog, M
    Diergarten, K
    Hanauske, AR
    ANNALS OF ONCOLOGY, 1998, 9 (03) : 335 - 337
  • [43] WEEKLY REGIMEN OF PACLITAXEL-CARBOPLATIN-CETUXIMAB AS FIRST-LINE CHEMOTHERAPY IN PATIENTS WITH PLATINUM-RESISTANT RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF HEAD AND NECK (SSCHN): RESULTS OF A PHASE II STUDY
    Rozzi, A.
    Lenci, G.
    Corona, M.
    Nardoni, C.
    Restuccia, M. R.
    Falbo, T.
    Nappa, M.
    Costa, A. M.
    Spigone, B.
    Lanzetta, G.
    ANNALS OF ONCOLOGY, 2010, 21 : 323 - 323
  • [44] Induction chemotherapy with cetuximab, carboplatin and paclitaxel for the treatment of locally advanced squamous cell carcinoma of the head and neck
    Bauman, Jessica
    Langer, Corey
    Quon, Harry
    Algazy, Kenneth
    Lin, Alexander
    Desai, Arati
    Mutale, Faith
    Weiss, Jared
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2013, 5 (04) : 1247 - 1253
  • [45] Simlukafusp a and cetuximab combination in patients with recurrent, unresectable or metastatic squamous cell carcinoma of the head and neck
    Hansen, A. R.
    Gomez-Roca, C. A.
    Lolkema, M. P.
    Verlingue, L.
    Italiano, A.
    Spicer, J.
    Steeghs, N.
    Bauman, J. E.
    Fayette, J.
    Niu, J.
    Prenen, H.
    Dejardin, D.
    Boetsch, C.
    Kraxner, A.
    Evers, S.
    Vardar, T.
    Keshelava, N.
    Teichgraber, V.
    Bonomi, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S805 - S805
  • [46] A phase II trial of vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
    Saxman, S
    Mann, B
    Canfield, V
    Loehrer, P
    Vokes, E
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1998, 21 (04): : 398 - 400
  • [47] Quality of life of elderly patients receiving weekly carboplatin and paclitaxel chemotherapy plus cetuximab first line for metastatic squamous cell carcinoma of the head and neck
    Lugini, A.
    Rossi, R.
    Pace, R.
    Rauco, A.
    Santarelli, M.
    Capparella, V.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S752 - S752
  • [48] A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck
    Enokida, Tomohiro
    Ogawa, Takenori
    Homma, Akihiro
    Okami, Kenji
    Minami, Shujiro
    Nakanome, Ayako
    Shimizu, Yasushi
    Maki, Daisuke
    Ueda, Yuri
    Fujisawa, Takao
    Motegi, Atsushi
    Ohkoshi, Akira
    Taguchi, Jun
    Ebisumoto, Koji
    Nomura, Shogo
    Okano, Susumu
    Tahara, Makoto
    CANCER MEDICINE, 2020, 9 (05): : 1671 - 1682
  • [49] Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma
    Shin, DM
    Glisson, BS
    Khuri, FR
    Ginsberg, L
    Papadimitrakopoulou, V
    Lee, JJ
    Lawhorn, K
    Gillenwater, AM
    Ang, KK
    Clayman, GL
    Callender, DL
    Hong, WK
    Lippman, SM
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) : 1325 - 1330
  • [50] RAMUCIRUMAB IN COMBINATION WITH PEMBROLIZUMAB AS FIRST-LINE TREATMENT FOR RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS-CELL CARCINOMA: A PHASE 1-2 TRIAL
    Adkins, Douglas
    Ley, Jessica
    Palka, Kevin
    Jacobs, Miriam
    Liu, Jingxia
    Oppelt, Peter
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A385 - A385
12345